Skip to main content
Top
Published in: Translational Behavioral Medicine 4/2016

01-12-2016 | Policy Brief

Society of behavioral medicine supports increasing HPV vaccination uptake: an urgent opportunity for cancer prevention

Authors: Caryn E. Peterson, PhD, J. Andrew Dykens, MD, Noel T. Brewer, PhD, Joanna Buscemi, PhD, Karriem Watson, MPH, MS, DeLawnia Comer-Hagans, PhD, Zo Ramamonjiarivelo, PhD, Marian Fitzgibbon, PhD

Published in: Translational Behavioral Medicine | Issue 4/2016

Login to get access

Abstract

Human papillomavirus (HPV) vaccine coverage remains low in the USA. The Society for Behavioral Medicine (SBM) supports the goals outlined by Healthy People 2020, the President’s Cancer Panel, and the National Vaccine Advisory Committee to increase vaccination coverage among both males and females. SBM makes the following recommendations in support of efforts to reduce structural and other barriers to HPV vaccination services in order to increase rates of series completion. We encourage legislators and other policymakers to improve administration authority, insurance coverage, and reimbursement rates to healthcare providers who make the HPV vaccine available to adolescents; provide instrumental support to fund the development of school curricula on HPV vaccination; and increase public awareness that HPV vaccination can prevent cancer. We urge healthcare providers and healthcare systems to increase the strength, quality, and consistency of HPV vaccination recommendations for all eligible patients; to treat HPV vaccination as a routine preventive service; employ culturally appropriate communication strategies in clinical settings to educate eligible patients, parents, and guardians about the importance, effectiveness, and safety of HPV vaccination; and to strengthen and better coordinate the use of electronic medical records and immunization information systems.
Literature
1.
go back to reference Satterwhite, C. L., et al. (2013). Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis, 40(3), 187–193.CrossRefPubMed Satterwhite, C. L., et al. (2013). Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis, 40(3), 187–193.CrossRefPubMed
2.
go back to reference Human, O. (2012). From the Centers for Disease Control and Prevention. JAMA, 308(5), 445. Human, O. (2012). From the Centers for Disease Control and Prevention. JAMA, 308(5), 445.
3.
go back to reference Bosch, F. X., et al. (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 87(11), 796–802.CrossRefPubMed Bosch, F. X., et al. (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 87(11), 796–802.CrossRefPubMed
4.
go back to reference Walboomers, J. M., et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189(1), 12–19.CrossRefPubMed Walboomers, J. M., et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189(1), 12–19.CrossRefPubMed
5.
go back to reference Maxwell, J.H., J.R. Grandis, and R.L. Ferris, HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Medicine. 2016; 67. Maxwell, J.H., J.R. Grandis, and R.L. Ferris, HPV-associated head and neck cancer: unique features of epidemiology and clinical management. Medicine. 2016; 67.
6.
go back to reference Alemany, L., et al., Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016. Alemany, L., et al., Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016.
7.
go back to reference Park, I. U., Introcaso, C., & Dunne, E. F. (2015). Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis, 61(suppl 8), S849–S855.CrossRefPubMed Park, I. U., Introcaso, C., & Dunne, E. F. (2015). Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis, 61(suppl 8), S849–S855.CrossRefPubMed
8.
go back to reference De Vuyst, H., et al. (2009). Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer, 124(7), 1626–1636.CrossRefPubMed De Vuyst, H., et al. (2009). Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer, 124(7), 1626–1636.CrossRefPubMed
9.
go back to reference Jemal, A., et al., Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)–associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013: djs491. Jemal, A., et al., Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)–associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013: djs491.
10.
go back to reference Marur, S., et al. (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol, 11(8), 781–789.CrossRefPubMed Marur, S., et al. (2010). HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol, 11(8), 781–789.CrossRefPubMed
11.
go back to reference Rimer, B., Harper, H., & Witte, O. (2014). Accelerating HPV vaccine uptake: urgency for action to prevent cancer; a report to the President of the United States from the president’s cancer panel. Bethesda, MD: National Cancer Institute. Rimer, B., Harper, H., & Witte, O. (2014). Accelerating HPV vaccine uptake: urgency for action to prevent cancer; a report to the President of the United States from the president’s cancer panel. Bethesda, MD: National Cancer Institute.
12.
go back to reference Schiffman, M., & Castle, P. E. (2005). The promise of global cervical-cancer prevention. N Engl J Med, 353(20), 2101–2104.CrossRefPubMed Schiffman, M., & Castle, P. E. (2005). The promise of global cervical-cancer prevention. N Engl J Med, 353(20), 2101–2104.CrossRefPubMed
13.
go back to reference Food, U., D. Administration, and F. approves Gardasil, for prevention of certain cancers caused by five additional types of HPV on December 10, 2014. Food, U., D. Administration, and F. approves Gardasil, for prevention of certain cancers caused by five additional types of HPV on December 10, 2014.
14.
go back to reference Monie, A., et al. (2008). Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics: Targets & Therapy, 2(1), 107. Monie, A., et al. (2008). Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics: Targets & Therapy, 2(1), 107.
15.
go back to reference Control, C.f.D. and Prevention (2010). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep, 59(20), 630. Control, C.f.D. and Prevention (2010). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep, 59(20), 630.
16.
go back to reference Petrosky, E., et al. (2015). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR, 64, 300–304.PubMed Petrosky, E., et al. (2015). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR, 64, 300–304.PubMed
17.
go back to reference Recommendations, H.V (2012). Commite on infectious disease. Pediatrics, 129, 602–605.CrossRef Recommendations, H.V (2012). Commite on infectious disease. Pediatrics, 129, 602–605.CrossRef
18.
go back to reference Kahn, J. A., et al. (2012). Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics, 130(2), e249–e256.CrossRefPubMedPubMedCentral Kahn, J. A., et al. (2012). Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics, 130(2), e249–e256.CrossRefPubMedPubMedCentral
19.
go back to reference Villa, L., et al. (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 95(11), 1459–1466.CrossRefPubMedPubMedCentral Villa, L., et al. (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 95(11), 1459–1466.CrossRefPubMedPubMedCentral
20.
go back to reference Reagan-Steiner, S., et al. (2015). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years–United States, 2014. MMWR Morb Mortal Wkly Rep, 64(29), 784–792.CrossRefPubMed Reagan-Steiner, S., et al. (2015). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years–United States, 2014. MMWR Morb Mortal Wkly Rep, 64(29), 784–792.CrossRefPubMed
21.
go back to reference Ng, J., et al. (2014). Human papillomavirus vaccination coverage among female adolescents in managed care plans—United States, 2013. MMWR. Morb Mortal Wkly Rep, 64(42), 1185–1189.CrossRef Ng, J., et al. (2014). Human papillomavirus vaccination coverage among female adolescents in managed care plans—United States, 2013. MMWR. Morb Mortal Wkly Rep, 64(42), 1185–1189.CrossRef
22.
go back to reference Berkowitz, Z., et al. (2015). Providers’ beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: findings from a provider survey, 2012. Prev Med, 81, 405–411.CrossRefPubMed Berkowitz, Z., et al. (2015). Providers’ beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: findings from a provider survey, 2012. Prev Med, 81, 405–411.CrossRefPubMed
23.
go back to reference Roland, K. B., et al. (2014). Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in US federally qualified health centers. Vaccine, 32(42), 5432–5435.CrossRefPubMedPubMedCentral Roland, K. B., et al. (2014). Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in US federally qualified health centers. Vaccine, 32(42), 5432–5435.CrossRefPubMedPubMedCentral
24.
go back to reference Gilkey, M. B., et al. (2015). Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol Biomark Prev, 24(11), 1673–1679.CrossRef Gilkey, M. B., et al. (2015). Quality of physician communication about human papillomavirus vaccine: findings from a national survey. Cancer Epidemiol Biomark Prev, 24(11), 1673–1679.CrossRef
25.
go back to reference Gilkey, M. B., et al. (2016). Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine, 34(9), 1187–1192.CrossRefPubMed Gilkey, M. B., et al. (2016). Provider communication and HPV vaccination: the impact of recommendation quality. Vaccine, 34(9), 1187–1192.CrossRefPubMed
26.
go back to reference Holman, D. M., et al. (2014). Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr, 168(1), 76–82.CrossRefPubMedPubMedCentral Holman, D. M., et al. (2014). Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr, 168(1), 76–82.CrossRefPubMedPubMedCentral
27.
go back to reference Dorell, C., et al. (2013). Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old national immunization survey–Teen, 2010. Clin Pediatr, 52(2), 162–170.CrossRef Dorell, C., et al. (2013). Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old national immunization survey–Teen, 2010. Clin Pediatr, 52(2), 162–170.CrossRef
28.
go back to reference Kessels, S. J., et al. (2012). Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine, 30(24), 3546–3556.CrossRefPubMed Kessels, S. J., et al. (2012). Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine, 30(24), 3546–3556.CrossRefPubMed
30.
go back to reference Btoush, R. M., et al. (2015). Initiation of human papillomavirus vaccination among predominantly minority female and male adolescents at inner-city community health centers. Am J Public Health, 105(11), 2388–2396.CrossRefPubMed Btoush, R. M., et al. (2015). Initiation of human papillomavirus vaccination among predominantly minority female and male adolescents at inner-city community health centers. Am J Public Health, 105(11), 2388–2396.CrossRefPubMed
Metadata
Title
Society of behavioral medicine supports increasing HPV vaccination uptake: an urgent opportunity for cancer prevention
Authors
Caryn E. Peterson, PhD
J. Andrew Dykens, MD
Noel T. Brewer, PhD
Joanna Buscemi, PhD
Karriem Watson, MPH, MS
DeLawnia Comer-Hagans, PhD
Zo Ramamonjiarivelo, PhD
Marian Fitzgibbon, PhD
Publication date
01-12-2016
Publisher
Springer US
Published in
Translational Behavioral Medicine / Issue 4/2016
Print ISSN: 1869-6716
Electronic ISSN: 1613-9860
DOI
https://doi.org/10.1007/s13142-016-0441-5

Other articles of this Issue 4/2016

Translational Behavioral Medicine 4/2016 Go to the issue